Numerate integrates platform with Google Compute Engine

Tuesday, July 3, 2012 09:36 AM

Numerate, a technology platform company that uses proprietary algorithms and cloud computing to transform the drug design process, has integrated its platform with Google Compute Engine.

Numerate's in silico drug design platform features a set of proprietary algorithms that use machine learning to provide predictive models for molecular properties with accuracies comparable to laboratory testing. Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.

"The development of new medicines is greatly constrained by the complexities and serendipity of traditional drug discovery methods," said Nigel Duffy, chief technology officer, Numerate. "We have built a new computational process to remove this bottleneck by assuming a world with unconstrained access to computational resources. Capabilities like Google Compute Engine make that assumption a reality, allowing us to meet the needs of our growing list of pharmaceutical collaborators."

Brandon Allgood, director of computational sciences at Numerate, added, “Google Compute Engine is a flexible and easy-to-use platform offering a clean, simple API, a powerful security model and the rapid provisioning of computational resources. Rapid provisioning is critical for us as we elastically scale to thousands of cores in response to our partners' needs. Google Compute Engine excels in this regard. In fact, with a small amount of effort, we adapted our platform to Google Compute Engine and have already scaled to more than 10,000 cores."

Numerate, whose drug design system is built on Numatix, an elastically scalable dataflow processing platform for cloud computing, is one of several Google Compute Engine partners.

"To help customers get the most out of our cloud platform products," explained Eric Morse, head of sales and business development for Google's cloud platform, "we work closely with technology companies that provide powerful complementary solutions integrated with our platform."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs